Publication List English

In vivo assessment of individual and total proteinuria in zebrafish larvae using the solvatochromic compound ZMB741

Generation of a Transgenic Zebrafish Line for In Vivo Assessment of Hepatic Apoptosis

Patient-Derived Cancer Xenograft Zebrafish Model (PDXZ) for Drug Discovery Screening and Personalized Medicine

Quality Control Protocol for Zebrafish Developmental Toxicity Studies

Gap junction protein beta 4 plays an important role in cardiac function in humans, rodents, and zebrafish

tTwo isoforms of cGMP-inhibited cyclic nucleotide phosphodiesterases in human tissues distinguished by their responses to vesnarinone, a new cardiotonic agent.


Masuoka H, Ito M, Sugioka M, Kozeki H, Konishi T, Tanaka T, Nakano T.
Biochem Biophys Res Commun. 1993 Jan 29;190(2):412-7.


We examined the inhibitory effects of vesnarinone, a new cardiotonic agent, on human cyclic nucleotide phosphodiesterase (PDE). Vesnarinone selectively inhibited the activity of human cardiac cGMP-inhibited PDE with a Ki value of 8.5 microM. The inhibition of human cardiac cGMP-inhibited PDE by vesnarinone was not competitive but was of the mixed type with respect to cAMP. Although the activities of the cGMP-inhibited PDE from human heart, aorta, platelets, and kidney were inhibited to the same extent by cGMP, enoximone, and cilostazole, vesnarinone inhibited the activities of cardiac and kidney cGMP-inhibited PDE with 10 times greater potency than those of platelet and aorta cGMP-inhibited PDE. These results suggest that there exist, in human tissues, two isoforms of cGMP-inhibited PDE that can be distinguished by reference to the inhibitory effects of vesnarinone.